For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How does the forecasted CAGR of the dyspnea industry compare to other sectors?
The dyspnea market size has grown strongly in recent years. It will grow from $6.26 billion in 2024 to $6.75 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising respiratory disease awareness, rising incidence of lifestyle related factors, growing geriatric population, increasing clinical trials, and growing supportive government initiatives.
The dyspnea market size is expected to see strong growth in the next few years. It will grow to $8.97 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing prevalence of chronic diseases, growing demand for personalized medicine, rising pollution, rising adoption of telemedicine, and growing favorable regulations. Major trends in the forecast period include strategic collaboration, technological advancements, development of novel inhalers, personalized medicine, and targeted therapies.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21178&type=smp
What market trends are acting as primary growth drivers for the dyspnea sector?
The increasing prevalence of respiratory diseases is expected to propel the growth of the dyspnea market going forward. Respiratory diseases are conditions that affect the lungs and other parts of the respiratory system, causing difficulty in breathing and impaired oxygen exchange. The common respiratory diseases include asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and more. The rise in respiratory diseases is driven by factors such as air pollution, smoking, environmental toxins, and climate change. Dyspnea aids in diagnosing and managing respiratory diseases by signaling lung function impairment, informing treatment strategies, and monitoring disease progression. For instance, in November 2023, according to the National Asthma Council, an Australia-based non-profit organization, in 2022, Australia reported 467 asthma-related deaths, including 299 females and 168 males, marking an increase from 355 deaths in 2021. Therefore, the increasing prevalence of respiratory diseases is driving the growth of the dyspnea market.
Impact Of Increasing Healthcare Expenditure On The Market
The increasing healthcare expenditure is expected to propel the growth of the dyspnea market going forward. Healthcare expenditure is the total financial resources spent on healthcare services, including public and private spending on medical care, hospital services, pharmaceuticals, and preventive measures. The increasing healthcare expenditure is attributed to the rising demand for advanced medical treatments, the aging population, and the growing prevalence of chronic diseases, which require continuous care and expensive interventions. The higher investments enable the development and accessibility of novel therapies, such as inhalers, oxygen therapy, and biologics, improving patient outcomes. Additionally, increased spending supports better healthcare infrastructure and specialized care, leading to early diagnosis and effective management of dyspnea-related conditions. For instance, in December 2023, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, in 2022, U.S. healthcare spending grew by 4.1%, totaling $4.5 trillion, reflecting a faster increase than the 3.2% growth seen in 2021. Therefore, the increasing healthcare expenditure is driving growth in the dyspnea market.
What are the fastest-growing segments in the dyspnea market forecast period?
The dyspnea market covered in this report is segmented –
1) By Treatment Type: Supplemental Oxygen Therapy, Relaxation Therapy
2) By Drug Class: Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, Other Drug Classes
3) By Route Of Administration: Oral, Inhalation, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Ambulatory Services, Other End Users
Subsegments:
1) By Supplemental Oxygen Therapy: Continuous Flow Oxygen Therapy, Pulse Dose Oxygen Therapy, Oxygen Concentrators, Portable Oxygen Cylinders
2) By Relaxation Therapy: Breathing Exercises, Meditation and Mindfulness, Progressive Muscle Relaxation, Biofeedback Therapy
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report
What technological trends are expected to redefine the dyspnea market?
Major companies operating in the dyspnea market are focusing on new drug developments, such as phosphodiesterase (PDE) inhibitors, to enhance treatment efficacy and provide better relief for patients with respiratory conditions. A phosphodiesterase (PDE) inhibitor is a drug that blocks the activity of phosphodiesterase enzymes, leading to increased levels of cyclic AMP or cyclic GMP in cells, which can enhance vasodilation, reduce inflammation, or improve cardiac function. For instance, in May 2024, Verona Pharma Plc, a UK-based biopharmaceutical company, announced that it is preparing for the anticipated U.S. launch of ensifentrine, a first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor for COPD treatment, in Q3 2024, pending FDA approval. Ensifentrine is a nebulized treatment for chronic obstructive pulmonary disease (COPD) that has demonstrated significant reductions in exacerbation rates and improvements in dyspnea in Phase III clinical trials. The company has secured $650 million in financing to support the drug’s commercial launch and ongoing development, including a planned Phase II trial for a fixed-dose combination with glycopyrrolate as a maintenance therapy for COPD patients.
Which major players hold significant market share in the dyspnea sector?
Major companies operating in the dyspnea market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Amgen Inc., Viatris Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Lincare Holdings Inc, Nephron Pharmaceuticals Corporation, Rotech Healthcare Inc., Inogen Inc, Lannett Inc., Ligand Pharmaceuticals Incorporated, OMRON Healthcare Inc, Flexicare Medical Ltd, Zydus Cadila Healthcare Ltd, Advacare Pharma, Airways surgical Pvt. Ltd., Belluscura Plc
Which regional segments are forecasted to witness the fastest growth in the dyspnea market?
North America was the largest region in the dyspnea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyspnea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Dyspnea Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21178
Need Customized Data On Dyspnea Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21178&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
